Acute Myelogenous Leukemia (AML) is a heterogenous disorder characterized by the inhibition of myeloid differentiation in hematopoietic progenitor cells.1 It is one of the most common types of leukemia among adults. This type of cancer is rare under age 40. Median age of patients with AML is 63 years.2 Clinically, patients present with fever, fatigue, and spontaneous mucosal and cutaneous bleeding, and frequently have opportunistic infections such as fungi and Pseudomonas.1 Most patients with AML achieve complete remission after chemotherapy and/or stem cell transplantation (SCT). 2 Unfortunately, the relapse is associated with high mortality rate with five year survival rates of approximately 50%.2 The most common cause of death is bone marrow failure resulting in anemia, neutropenia, and thrombocytopenia.1 Currently, AML is diagnosed based on a combination of morphology, cytochemistry, flow cytometry and cytogenetics.1 The most important prognostic information in adult AML is karyotype.2 However, approximately 50% of AML patients lack chromosomal aberrations, and for these patients molecular genetic approaches are of major importance. 2
In addition to chromosomal translocations, numerous mutations are associated with AML, and they are frequently found in cytogenetically normal (CN) AML.3 However, to date only diagnosis of NPM1, CEBPA and FLT3 mutations have entered clinical practice and are used as tools for diagnosis, prognosis and therapy assessment.3 Discovery of these mutations has been shown to be of major importance, they are important diagnostic as well as prognostic markers. NPM1 is nuclear-cytoplasmic shuttling phosphoprotein with pleiotropic functions. Mutations lead to abnormal cytoplasmic loc...
... middle of paper ...
...ournal of Clinical Oncology. 2011.29.5:475-486.
4. Garcia-Manero G.,Gore D.S.,at all. Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia. Journal of Clinical Oncology. 2011.29:2521-3537.
5. Parkin B.,Ouillette P., at all. NF1 Inactivation in Adult Acute Myelogenous Leukemia. Clin Cancer Res. 2010. 16(16):4135-4147.
6. Jonge H.J.M.,Huls G.,Bont E. Gene Expression Profiling in Acute Myeloid Leukemia. The Journal of Medicine. 2011. 69(4):167-176.
7. European Leukemia Net. URL:http://www.leukemia-net.org/content/e58/e480/e6041/e6619/index_eng.html
8. Valk P.,Verhaek R.,at.all. Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia. The New England Journal of Medicine. 2004. 350(16):1617-1628.
9. http://www.skyline-diagnostics.com/products/amlprofiler/three-days-to-diagnosis/
The University of Texas MD Anderson Cancer Center states the disease is divided into two major types namely acute and chronic. The acute types of the disease are those that progress quickly and involve an overgrowth of very immature blood cells. This becomes life threatening because very few mature cells mean that the body loses its ability to prevent infection, anemia and bleeding disorders. A diagnosis of the acute type is given when the immature cells found account for 20% or more of the blood cells produced. The chronic type progress slowly and involves an overgrowth of mature blood cells. In contract to the acute type people affect by this type usually h...
95% of the genetic mutations resulting in CLL are in B-cells. The other 5% are in T- or NK-cells. These mutations result in abnormal lymphocytes (leukemic cells). As the cancer progresses from the blood to the marrow, the increased number of cancerous cells push healthy white blood cells, red blood cells and platelets out of the bone marrow. This “takeover” of the marrow can result in anemia, reduced ability to fight infection and easy bleeding. The increased rates of secondary infections are the result of decreased infection-fighting capacity of white blood cells.
This mutation is associated with particularly poor outcome and resistance to front-line treatment with fludarabine, cyclophosphamide and rituximab(FCR)(26). In clinical trials, treatment of del(17p) CLL with FCR only achieve complete remission in 5% of patients and overall survival is only 38% at 3years (27). The key gene effected by the 17p deletion is tumour protein p53(TP53), which has an integral role in the induction of apoptosis or cell cycle arrest following DNA damage(28). 80-90% of CLL patients with the 17p deletion have also been shown to have TP53 mutation on the remaining copy, thus disabling the apoptotic pathway in the malignant cells. Interphase FISH is suitable for identifying del(17p) however it does not detect mutations in TP53, which can have the same poor prognosis and treatment refractoriness(29). Between 13.5-26% of CLL cases have dysfunctional/non-functional TP53 gene which is considerable more than the 7% which have
Compare and contrast acute lymphocytic leukemia and acute myelogenous leukemia in children. What are possible presenting features and diagnostic criteria? What are the cure rates with treatment?
- Acute myelogenous leukemia (AML): Is a cancer of the bone marrow and the blood that will progress quickly without treatment. This type of leukemia affects mainly the cells that aren’t fully developed. Therefore, making the cells not carry out their normal functions. With this type of dysfunctional activity in the cells at an early stage, this why it is very important to get care and treatment as soon as possible.
Yearly, around six hundred to nine hundred people are diagnosed with Aplastic Anemia within the United States. Aplastic Anemia is a autoimmune hematological disorder that causes pancytopenia which is a reduction in major blood components, namely, erythrocytes, leukocytes and platelets. This disease has been labelled as a type of bone marrow failure, that is often due to not one but a variety of disorders that occur simultaneously. Aplastic Anemia can therefore be defined as a bone marrow disorder that is often rare, non contagious, and can often be life threatening.
Yurchenko, M., L. M. Shlapatska, and S. P. Sidorenko. (13 Aug, 2012) Figure. Digital image. Experimental Oncology. Morion. Web. 16 Apr. 2105. Retrieved from: http://exp-oncology.com.ua/article/3373/the-multilevel-regulation-of-cd95-signaling-outcome
Because FA affects the function of the bone marrow and eventually leads to bone marrow failure, an adequate amount of red, and white blood cells, and platelets are not produced. When there is a deficiency in red blood cells patients may experience “weakness, fatigue, and a pale appearance” yet, when a person's body doesn't produce enough white blood cells they “may be vulnerable to common germs and infections.” Additionally, a person who has an inability to produce blood platelets suffers from “easy bruising, nosebleeds, and possible internal bleeding” (Freivogel). In addition to bone marrow failure, around ten to fifteen percent of people with FA are diagnosed with leukemia, “specifically acute myelogenous leukemia (AML)” (Freivogel). leukemia affects the blood system, causing your body to rapidly produce abnormal white blood cells which suppresses the production of healthy white blood cells. To make matters worse when a patient has FA it makes them extremely sensitive to the harsh drugs used in treating leukemia making it very difficult to treat. Hyperpigmentation was recorded in “approximately 65% of patients” (Freivogel). Hyperpigmentation is a darkening of the skin, it can appear in spots or splotches, or it can cover a larger area of the individual's skin. The symptoms of FA are very
...l risk factors that are fully linked developing multiple myeloma. Therefore, preventative measures remain unknown.
As noted in a review of the retrieved articles, different types of medications were used as treatment for leukemia. Many research studies were conducted in order to find a way to limit the progression of leukemia. Leukemia is a rapid replication of atypical white blood cells (WBCs) that reduces the ability of WBCs to fight the infection (American Society of Hematology). Leukemia is classified into types: myeloid and lymphoid leukemia. Myeloid /lymphoid leukemia has acute and chronic phases. Acute myeloid leukemia (AML) is an increase of myoblasts in peripheral blood or bone marrow (Kantarjian et al., 2010). This study used a comparison method to check the effect of intensive chemotherapy in older patients with AML (Kantarjian et al., 2010). Chemotherapy is a standard treatment for leukemia (Buizer et al., 2009). Older Patients with AML were excluded from the AML therapy trial (Kantarjian et al., 2010). Recently, researchers have focused on the older population with AML who received intensive chemotherapy many years ago (Kantarjian et al., 2010). Patients 65-69 years old and patients with Myelodysplastic syndrome (MDS) were included in this study (Kantarjian et al., 2010). χ2 test was involved in this research to compare between the variables (Kantarjian et al., 2010). Age was tested as continuous variables (Kantarjian et al., 2010). In addition, mortality rate...
Campbell N. A., Reece L. A., Cain M. L., Wasserman S. A., Minorsky P. V. and Jackson R. B. (2008). Regulation of Gene Expression
Muller, Patrick Y., et al. "Short technical report processing of gene expression data generated by quantitative Real-Time RT-PCR." Biotechniques 32.6 (2002a): 1372-1379.
The Acute myeloid leukemia is when the bone marrow makes abnormal myeloblasts. Myeloblast is a type of white blood cell which doesn’t produce a white blood cell. It mostly occurs in man after their 60s, having chemotherapy in the past and in the past, you have had leukemia. Some of the symptoms are fever, shortness of breaths, easy bruising or bleeding, always tired and loss of hunger. AML is not hereditary, so it does not run in the family history. There is no cure but, there are treatments for it like chemotherapy.
Four common types of leukemia exist affecting different people of all ages. Chronic Lymphocytic Leukemia (CLL) is a disease that usually grows slowly in the body and affects lymphoid cells. It accounts for 15,000 new cases each year, and affects mainly people over the age of 55, rarely affecting children. Chronic Myeloid Leukemia (CML) on the other hand affects myeloid cells and tends to develop slowly at first. As well as CLL, it mainly affects adults, and is a disease that is accounted for nearly 5,000 new cases each year. Acute Myeloid Leukemia (AML) affects myeloid cells, just as CML disease. This type of disease grows quickly and occurs in both children and adults, with 13,000 cases each year. Acute Lymphocytic (lym...
Transcriptomics- the study of gene expression (Sorek & Cossart, 2010; Stewart, Sharma, Bryant, Eppley, & DeLong, 2011; Z. Wang, Gerstein, & Snyder, 2009)